اگلا

آٹو پلے

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

1 مناظر • 07/16/23
بانٹیں
ایمبیڈ
administrator
administrator
سبسکرائبرز
0

Visit http://www.ecancer.org for more

Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

مزید دکھائیں
0 تبصرے sort ترتیب دیں
فیس بک کے تبصرے

اگلا

آٹو پلے